Smithson Pharmaceuticals India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -20.03%
- Profit Growth -0.67%
- Ebitda 1.10%
- Net Worth 10.74%
- Total Assets 35.18%
About Smithson Pharmaceuticals India
Smithson Pharmaceuticals India Private Limited (SPIPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 May 2015 (Nine years and nine months 22 days old ). Its registered office is in Indore, Madhya Pradesh, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sunil Mujawadiya and Smita Shrivastava serve as directors at the Company.
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230MP2015PTC034163
- Company No.
034163
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 May 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Smithson Pharmaceuticals India?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunil Mujawadiya  | Director | 05-May-2015 | Current |
| Smita Shrivastava | Director | 05-May-2015 | Current |
Financial Performance of Smithson Pharmaceuticals India.
Smithson Pharmaceuticals India Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 20.03% decrease. The company also saw a slight decrease in profitability, with a 0.67% decrease in profit. The company's net worth Soared by an impressive increase of 10.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Smithson Pharmaceuticals India?
In 2017, Smithson Pharmaceuticals India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Smithson Pharmaceuticals India?
Unlock and access historical data on people associated with Smithson Pharmaceuticals India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Smithson Pharmaceuticals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Smithson Pharmaceuticals India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.